Arsenic Patents (Class 424/620)
  • Patent number: 10058570
    Abstract: The present invention relates to the use of arsenic compounds such as sodium meta arsenite (NaAsO2), arsenic trioxide (As2O3), and arsenic hexoxide (As4O6) or combinations thereof, for the treatment of painful, hyperalgesic and/or inflammatory conditions. The present invention also relates to compositions containing the above arsenic compounds for use in the treatment of pain, inflammation and immunological and autoimmune diseases and disorders.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: August 28, 2018
    Assignee: Panaphix Inc.
    Inventors: Michael Hwang, Yong Jin Yang
  • Patent number: 8834938
    Abstract: A method of inhibiting, preventing, or reducing damage to non-cancerous cells in a human subject during chemotherapeutic treatment or radiation treatment of cancer cells in the human subject includes administering to the human subject arsenic and/or one or more compounds of arsenic in a therapeutically effective amount prior to treatment with radiation or one or more chemotherapeutic agents.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: September 16, 2014
    Assignee: Board of Regents of the University of Texas System
    Inventor: Zhi-Min Yuan
  • Patent number: 8795738
    Abstract: A method of inhibiting damage to non-cancerous cells in a human subject during chemotherapeutic treatment or radiation treatment of cancer cells in the human subject includes administering to the human subject arsenic and/or one or more compounds of arsenic in a therapeutically effective amount prior to treatment with radiation or one or more chemotherapeutic agents.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: August 5, 2014
    Assignee: Board of Regents of the University of Texas System
    Inventor: Zhi-Min Yuan
  • Patent number: 8784797
    Abstract: The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a combination of an interferon, an arsenic compound and a reverse transcriptase inhibitor for the treatment of Adult T-cell leukemia/lymphoma.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: July 22, 2014
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), American University of Brirut
    Inventors: Hugues De The, Ali Bazarbachi, Olivier Hermine
  • Publication number: 20140193371
    Abstract: A method for preventing and treating one or more disease states including the steps of altering the diet of an individual and then administering a drug to the individual. Plasma vitamin C level is reduced from a first level to a second level that is lower than the first level, such that a pharmacological response of the body of the individual to a drug at the first level is different from the pharmacological response of the body of said individual to the drug at the second level.
    Type: Application
    Filed: January 7, 2014
    Publication date: July 10, 2014
    Inventor: Harold Edward Siess
  • Patent number: 8497300
    Abstract: The invention relates to the use of an arsenic compound for the preparation of a medicament that is used to treat autoimmune diseases.
    Type: Grant
    Filed: October 2, 2008
    Date of Patent: July 30, 2013
    Assignee: Centre National de la Recherche Scientifique (CNRS)
    Inventors: Kmar Chelbi Alix, Pedro Bobe
  • Publication number: 20120301409
    Abstract: A homeopathic composition and method for treating a variety of skin irritations, wounds, and diseases is disclosed. The homeopathic composition may contain as active ingredients salicyclic acid, trona or one of its salts, and at least one homeopathic agent.
    Type: Application
    Filed: May 23, 2011
    Publication date: November 29, 2012
    Inventors: Ned L. Jensen, Peter E. Fuller
  • Publication number: 20120164238
    Abstract: A method of detecting a predisposition to, or the incidence of colorectal cancer in a faecal sample comprises, in a first step (a), detecting the presence of blood in the faecal sample, wherein detection of the presence of blood is indicative of a predisposition to, or the incidence of colorectal cancer. The method additionally comprises, in second step (b), detecting an epi-genetic modification in the DNA contained within the faecal sample, wherein detection of the epigenetic modification is indicative of a predisposition to, or the incidence of colorectal cancer. Based upon a positive result obtained in either (a) or (b) or in both (a) and (b) a predisposition to, or the incidence of colorectal cancer is detected. Related methods and kits involve detecting an epigenetic modification in a number of specific genes.
    Type: Application
    Filed: February 3, 2010
    Publication date: June 28, 2012
    Inventor: Louwagie Joost
  • Patent number: 8168224
    Abstract: The present disclosure relates to a kind of sodium alginate microsphere vascular embolus that contains water-soluble drug and preparation and application thereof. The embolus preparation falls into dry microsphere type and wet one that are made of degradable materials. The drug carrier can be sodium alginate, human serum albumin, chitosan or sodium hyalurate, solidifying and forming microsphere together with calcium ion solution under presence of static charge. The microsphere can have a diameter in the range of 20-1000 ?m and can be divided into a wide variety of sizes in case of need. The present disclosure adopts raw materials that are good at mechanical strength, bio-compatibility, bio-degradability and stability.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: May 1, 2012
    Assignee: Beijing Shengyiyao Science & Technology Development Co., Ltd.
    Inventors: Li Xiaoping, Li Xinjian, Cui Heng, Wei Lihui, Feng Jie, Lang Jinghe, Xiang Yang, Lei Chengzhi, Hong Hong
  • Publication number: 20120027870
    Abstract: A method of detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises detecting an epigenetic change in at least one gene selected from FOXE1 and GATA4. Detection of the epigenetic change is indicative of a predisposition to, or the incidence of, bladder cancer. The sample comprises nucleic acid molecules from bladder cells. The methods may be used to select treatments and patients for treatment. Related kits include primers allowing the methylation status of the genes to be determined.
    Type: Application
    Filed: March 11, 2010
    Publication date: February 2, 2012
    Applicant: MSxHealth SA
    Inventor: Joost Louwagie
  • Publication number: 20110256235
    Abstract: The present invention relates to a method for protecting a human patient or a mammalian animal to be subjected to chemotherapy treatment of a tumor not residing in the scalp of the patient or the skin of the animal against chemotherapy-induced alopecia, comprising administering to the scalp of the patient or the skin of the animal an effective amount of a composition comprising a chemical inducer of the stress protein response sufficiently prior to the administration of a chemotherapeutic drug. It also relates to pharmaceutical compositions for the prevention of chemotherapy-induced alopecia. It further relates to a method for protecting a human patient or a mammalian animal to be subjected to chemotherapy treatment of a tumor not residing in the scalp of the patient or the skin of the animal against chemotherapy-induced alopecia, comprising administering to the scalp of the patient or the skin of the animal an effective heat dose sufficiently prior to the administration of a chemotherapeutic drug.
    Type: Application
    Filed: June 28, 2011
    Publication date: October 20, 2011
    Applicant: HSF PHARMACEUTICALS S.A.
    Inventor: RICHARD W. VOELLMY
  • Publication number: 20110250259
    Abstract: Breast cancer is a common cancer in women. Early diagnosis and treatments are vital for better outcomes. This formula consists of a liquid anti-disease anti-cancer formula that can be delivered to the source where breast cancer begins. Method of treating breast disease, including cancer, with a formula and a means of delivery with a topical, intraductal, ductal, and/or intraductal infusion to prevent the formation of cancer or precursors to cancer or atypia or other form of abnormal breast tissue or to treat breast diseases of all kinds. May include homeopathic remedies to be used topically or inside the breast with a delivery method to those regions and may be processed with or without photonic programming or an ionic delivery system for greater effectiveness and use against degenerative diseases or cancerous or precancerous diseases, precursors of breast disease, inflammatory breast disease, or accumulation of toxins in the breast tissue.
    Type: Application
    Filed: April 12, 2010
    Publication date: October 13, 2011
    Inventor: Kevin Buckman
  • Patent number: 7803350
    Abstract: This invention provides a process for producing a radioactive arsenic-containing compound, comprising the steps of: (i) subjecting an arsenic-containing compound to a neutron irradiation treatment, said arsenic-containing compound being selected from a group consisting of As2O3, As2S3, As2S2, and a combination thereof, such that the arsenic element contained in the arsenic-containing compound is converted to a radioactive arsenic isotope; and (ii) recovering the resultant product from step (i). This invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the radioactive arsenic-containing compound and a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the treatment of tumors/cancers such as hematological malignancies and solid tumors.
    Type: Grant
    Filed: July 30, 2007
    Date of Patent: September 28, 2010
    Assignees: Institute of Nuclear Energy Research Rocaec, TTY Biopharm Company, Limited
    Inventors: Te-Wei Lee, Chun-Ying Huang, Ming-Shiuan Wu, Te-Jung Chen, Kwo-Ping Chang, Shiang-Rong Chang, Shyh-Yi Chyi, Chih-Hsien Chang, Yin-Mao Hsu, Kuo-Hsien Fan, Wei-Chuan Hsu, Ying-Kai Fu, Charng-Feng Kao
  • Publication number: 20090214500
    Abstract: The present invention relates to compositions and methods for preventing and treating osteochondrosis by administration of supplemental boron containing compounds to animals and humans. The supplemental boron containing compounds are provided in animal feed compositions or as supplements for animal feed. Also provided by this invention are animal feed compositions that are supplemented with boron containing compounds and which have reduced phosphorus content. The invention also provides a method for treating or preventing osteochondrosis in animals or humans by the administration of supplemental boron containing compounds. The invention also provides a method for decreasing the amount of phosphorus excreted by an animal, a method of increasing the efficiency of absorption of phosphorus by an animal, a method of reducing environmental phosphorus pollution by administering supplemental boron to the animal.
    Type: Application
    Filed: June 2, 2006
    Publication date: August 27, 2009
    Applicant: U.S. Borax Inc.
    Inventors: Edgar W. Johnson, Larry M. Jayroe
  • Publication number: 20090192040
    Abstract: The invention provides a plant supporting formulation which is also suitable for use as a delivery vehicle, or a component of a delivery vehicle, for the delivery of one or more phytologically beneficial substances to a plant, and for enhancing the translocation of such delivered substance(s) in or on the plant, the formulation comprising a micro-emulsion constituted by a dispersion of vesicles or microsponges of a fatty acid based component in an aqueous carrier, the fatty acid based component comprising at least one long chain fatty acid based substance selected from the group consisting of free fatty acids and derivatives of free fatty acids. The dispersion is preferably characterized in that at least 50% of the vesicles or microsponges are of a diametrical size of between 50 nm and 5 micrometers.
    Type: Application
    Filed: February 23, 2007
    Publication date: July 30, 2009
    Applicant: North-West University
    Inventor: Anne Frederica Grobler
  • Publication number: 20090175957
    Abstract: A composition is provided which comprises an acidic component, generally fulvic acid, having a molecular weight not exceeding 20,000 Daltons and a low content of the elements aluminium, mercury, cadmium, chromium and lead. The acidic component is preferably carbohydrate derived and preferably using a wet oxidation process.
    Type: Application
    Filed: April 26, 2007
    Publication date: July 9, 2009
    Applicant: PFEINSMITH S.A. (pty) LTD
    Inventors: Earle John Loxton, Rudolph Johannes Malan, Stefan Coetzee
  • Patent number: 7531503
    Abstract: The invention is directed to methods and compositions for preparing matrices for controlled delivery of at least one therapeutic or biological agent to a target site in a subject. This is accomplished using nanoparticles coupled to the therapeutic or biological agent that are incorporated within the matrix or reacted on the surface of the matrix.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: May 12, 2009
    Assignee: Wake Forest University Health Sciences
    Inventors: Anthony Atala, James Yoo, Grace Lim, Richard Czerw, Shay Soker, Joel Stitzel
  • Publication number: 20090098216
    Abstract: The invention relates to the use of an arsenic compound for the preparation of a medicament that is used to treat autoimmune diseases.
    Type: Application
    Filed: October 2, 2008
    Publication date: April 16, 2009
    Inventors: Kmar Chelbi Alix, Pedro Bobe
  • Publication number: 20080175913
    Abstract: The present invention relates to wood preservative compositions comprising an effective amount of a pyrethroid compound in combination with an isothiazolone compound, methods and processes for preserving wood using the wood preservative compositions of the invention, and wood comprising the wood preservative compositions of the invention.
    Type: Application
    Filed: January 9, 2008
    Publication date: July 24, 2008
    Inventors: Jun Zhang, Richard J. Ziobro
  • Publication number: 20080057136
    Abstract: The invention relates to antimicrobial compositions that can be used for disinfecting and can be applied in various aspects of the national economy, medicine, and laboratories of all types. The antimicrobial compositions comprise a chelating metal complex compound with a monodentate bidentate or polydentate ligand that exhibits affinity to hydrogen ion, an ionogenic surfactant, and a solvent. The compositions of the invention display antiseptic properties. The antimicrobial compositions are active against Gram-positive and Gram-negative bacteria, fungi, viruses, and spores, and can be applied in a broad temperature interval. Methods of using the compositions of the present invention in the treatment and prevention of diseases caused by a variety of pathogens are further provided.
    Type: Application
    Filed: November 11, 2004
    Publication date: March 6, 2008
    Applicant: Veckis Industries Ltd.
    Inventors: Victor S. Polyakov, Valeriy V. Ermilov, Vladimir S. Kuzmin, Oleg I. Lukashov
  • Patent number: 7261906
    Abstract: A process for preparing As4O6 comprises successively heating and cooling a mixture of natural Sinsuk and 40% alcohol in a ratio of about 1: about 1 for about 1 to about 2 hour(s) resulting in a product, successively washing the product with distilled water thereby forming washed precipitates, maintaining the washed precipitates at about ?40° C. for 24 hours, defrosting, filtering, and drying the precipitates, and successively heating and cooling the precipitates to obtain the final As4O6 product.
    Type: Grant
    Filed: May 16, 2003
    Date of Patent: August 28, 2007
    Inventors: Ill-Ju Bae, Jong-Bae Kim, Choong-Ki Eun, Seung-Kyu Song, Byung-Sun Suh, Kwan-Hee Lee, Myoung-Sool Doo, Jin-Hwan Kwak, Byung-Doo Song, Taek-Joon Yoon, Tae-Bong Kang, Choon-Ho Park
  • Patent number: 7217413
    Abstract: The invention concerns the use of novel agents including cell death, and in particular, an agent for overexpression of the PML protein on nuclear bodies, combined with interferons, to induce the death of undesirable cells and simulate an immune reaction.
    Type: Grant
    Filed: July 30, 1999
    Date of Patent: May 15, 2007
    Assignees: Institut de la Sante et de la Recherde Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS)
    Inventors: Marcel Koken, Frédérique Quignon, Hugues De The, Jean-Claude Ameisen, Frédéric De Bels
  • Patent number: 7205001
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: April 17, 2007
    Assignee: Polarx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Marmelstein
  • Patent number: 7179493
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: February 20, 2007
    Assignee: PolaRx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Marmelstein
  • Patent number: 7163703
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: August 14, 2003
    Date of Patent: January 16, 2007
    Assignee: PolaRx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Mermelstein
  • Patent number: 7138147
    Abstract: The present invention relates to arsenic sulfide compounds. The present invention also relates to pharmaceutical compositions useful for treating cancer, such as leukemia or lymphoma, which comprises an arsenic sulfide compound. The present invention further relates to methods for treating cancer, such as leukemia or lymphoma, using an arsenic sulfide compound. Finally, the present invention relates to processes for producing arsenic disulfide (As4S4).
    Type: Grant
    Filed: August 7, 2003
    Date of Patent: November 21, 2006
    Inventor: Daopei Lu
  • Patent number: 6949665
    Abstract: The invention provides anti-thiol reagents which inhibit enzyme activity of cell-associated protein disulfide isomerase (PDI) by oxidizing or blocking PDI active site vicinal thiol groups which normally participate in disulfide bond rearrangement of PDI substrates. Inhibition of this PDI function is particularly useful in blocking PDI-mediated entry of HIV or other virions into a host cell, as well as inhibiting lymphocyte traffic through the lymph nodes. The invention further provides an assay for the identification of such PDI inhibitors based on the discovery that inhibitors of the invention also induce shedding of the leucocyte L-selectin adhesion molecule.
    Type: Grant
    Filed: December 5, 2001
    Date of Patent: September 27, 2005
    Assignee: Science & Technology Corporation @ UNM
    Inventors: Snezna Rogelj, Larry A. Sklar, Robert B. Palmer
  • Patent number: 6939566
    Abstract: Microbicidal formulations are described which are preferably ecologically friendly and non-toxic to mammals, and are highly effective against a broad spectrum of detrimental pathogenic microorganisms. The microbicidal formulation contains complexes having the formula R-M, wherein R is at least one organic chelating moiety and M is at least one metal ion which is microbicidal to at least one microorganism. These complexes can disrupt microorganism activities by penetrating the natural protecting bio-films of such microorganisms through the reaction of the R-group with the organic constituents of these microorganisms while releasing M into their intra-cellular media. Thus, this process exhibits its biocidal activities from the inside-out, contrary to other methods which rely on damaging the protective biofilms.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: September 6, 2005
    Inventors: Kareem I. Batarseh, Marwan Al-Kayed
  • Patent number: 6875451
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: October 15, 1998
    Date of Patent: April 5, 2005
    Assignee: PolaRx Biopharmaceuticals Inc.
    Inventors: Ralph M. Ellison, Fred H. Mermelstein
  • Patent number: 6861075
    Abstract: A storage-stable biocidal aerated gel composition comprises from 30 to 97% by weight of water, from 0.2 to 5% by weight of a gelling agent selected from xanthan gum, sodium alginate and neutralised carboxyvinyl polymer from 2 to 5% by weight of a fine particulate, hydrophobic silicone-treated silica having a surface area of from 80 to 300 m2/g and from 0.004 to 20% by weight of a biocide which said composition is in the form of fine particles of an aqueous gel containing the water, gelling agent and the biocide, the surfaces of which fine particles are coated with a coating of the finely particulate hydrophobic silica. The biocidal aerated gel composition can be used to control pests using one or more appropriate biocides in the composition.
    Type: Grant
    Filed: April 6, 2001
    Date of Patent: March 1, 2005
    Assignee: Sorex Limited
    Inventor: Roland S. Twydell
  • Patent number: 6764692
    Abstract: A method of treating laminitis in a horse is disclosed, comprising administering to the horse a naturally chelated trace mineral composition; promoting healthy skin, hair and hoof tissue. A method of reducing dietary intake is also disclosed, comprising administering to a horse in need thereof, effective amounts of a naturally chelated trace mineral composition. A method of preparing the chelated trace mineral composition from ocean seabed rock is further disclosed, as well as the chelated trace mineral composition.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: July 20, 2004
    Inventor: Carlos Cortelezzi
  • Patent number: 6733792
    Abstract: The present invention relates to arsenic sulfide compounds. The present invention also relates to pharmaceutical compositions useful for treating cancer, such as leukemia or lymphoma, which comprises an arsenic sulfide compound. The present invention further relates to methods for treating cancer, such as leukemia or lymphoma, using an arsenic sulfide compound. Finally, the present invention relates to processes for producing arsenic disulfide (As4S4).
    Type: Grant
    Filed: July 6, 1998
    Date of Patent: May 11, 2004
    Inventor: Daopei Lu
  • Patent number: 6723350
    Abstract: The invention provides methods and kits to form water swellable gel coatings, preferably lubricious coatings, on substrates, and coated substrates thus formed. The coatings contain one or more antimicrobial metals formed with atomic disorder, together with one or more antimicrobial metals formed with atomic disorder such that the coatings provide an antimicrobial and anti-inflammatory effect when wet. The invention also provides a method to produce metal powders by sputtering a coating onto a moving surface, and then scraping the coating with one or more scrapers to produce the metal powder. The method is particularly useful for producing large amounts of nanocrystalline antimicrobial metal powders formed with atomic disorder, useful in the water swellable gel coatings of this invention.
    Type: Grant
    Filed: April 23, 2002
    Date of Patent: April 20, 2004
    Assignee: Nucryst Pharmaceuticals Corp.
    Inventors: Robert Edward Burrell, Hua Qing Yin, Antony George Naylor, Peter Howard Moxham, Walter Carlton Theodore Cholowski, Leonard Salvin Bowlby, David James Field
  • Patent number: 6716458
    Abstract: The is invention is directed to a composition useful for assisting in supplying a warm-blooded animal with many of its nutritional needs. More specifically, this invention is directed to a composition whereby many of the vitamins, minerals, amino acids and cofactors are suspended in a matrix which when administered to a mammal provides substantial benefit.
    Type: Grant
    Filed: August 7, 2000
    Date of Patent: April 6, 2004
    Inventor: Bryon J. Tarbet
  • Patent number: 6630172
    Abstract: Disinfectant formulations are described which are preferably ecologically friendly and non-toxic to mammals and plants, and are highly effective against a broad spectrum of detrimental pathogenic microorganisms. The microbicidal formulation contains complexes having at least one metal ion which is microbicidal to at least one microorganism and potassium sodium tartrate in some form. When potassium sodium tartrate is used with these metal ions, it enhances the complex-forming properties of such metal complexes while concurrently increases their efficacy and potency at the same level of metal ion concentrations. These microbicidal formulations can be diluted in suitable proportions into aqueous systems to produce the desired dosages for each individual case, depending on the level and the severity of the contamination. The microbicidal formulations can be applied by conventional methods, e.g., spraying, soaking, fogging, impregnation, and the like.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: October 7, 2003
    Inventor: Kareem I. Batarseh
  • Publication number: 20030099716
    Abstract: Present invention relates to a method and composition for symptomatic relief of vaginitis. Until the treatment of underlying cause takes effect women suffer from unpleasant symptoms of vaginitis restricting daily routine activities. The symptoms of vaginitis may be incapacitating and are a common reason for visiting the gynecologist and can lead to frustration, embarrassment, anger, lost days from work, marital conflict and loss of ability to enjoy a normal personal, professional and social life.
    Type: Application
    Filed: November 27, 2002
    Publication date: May 29, 2003
    Inventor: Syed Ritzi
  • Publication number: 20030077304
    Abstract: Composition for topical administration comprising (a) a corticosteroid, and (b) a drying agent.
    Type: Application
    Filed: November 12, 2002
    Publication date: April 24, 2003
    Inventor: Michael E. McCadden
  • Patent number: 6521265
    Abstract: A method of arresting the flow of blood and other protein containing body fluids flowing from an open wound and for promoting wound healing. In the method, a substantially anhydrous compound of a salt ferrate is provided for a unique use which, when hydrated after mixing with a victim's own blood or other aqueous media, produces Fe+++ thereby promoting clotting when applied in a paste form to the wound for a time sufficient to arrest substantial further blood and other body fluid flow from the wound. The compound is formed of a ferrate (VI) salt taken from the group consisting of H, Li, Na, K, Rb, Cs and Fr. However, to decrease or eliminate stinging sensation, the compound may be formed having a ferrate (VI) salt taken from the group consisting of Be, Mg, Ca, Sr, Ba, Ra, Ti, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Ge, Zr, Nb, Mo, Tc, Ru, Rh, Pd, Ag, Cd, In, Sn, Hf, Ta, W, Re, Os, Ir, Pt, Au, Hg, TI, Pb, Bi, Al, As, NH4 and N(C4H9)4.
    Type: Grant
    Filed: June 13, 2000
    Date of Patent: February 18, 2003
    Assignee: Biolife, L.L.C.
    Inventor: James A. Patterson
  • Publication number: 20020001629
    Abstract: The present invention relates to a method for protecting a human patient or a mammalian animal to be subjected to chemotherapy treatment of a tumor not residing in the scalp of the patient or the skin of the animal against chemotherapy-induced alopecia, comprising administering to the scalp of the patient or the skin of the animal an effective amount of a composition comprising a chemical inducer of the stress protein response sufficiently prior to the administration of a chemotherapeutic drug. It also relates to pharmaceutical compositions for the prevention of chemotherapy-induced alopecia. It further relates to a method for protecting a human patient or a mammalian animal to be subjected to chemotherapy treatment of a tumor not residing in the scalp of the patient or the skin of the animal against chemotherapy-induced alopecia, comprising administering to the scalp of the patient or the skin of the animal an effective heat dose sufficiently prior to the administration of a chemotherapeutic drug.
    Type: Application
    Filed: August 24, 2001
    Publication date: January 3, 2002
    Inventor: Richard W. Voellmy
  • Publication number: 20010021394
    Abstract: The present invention relates to compositions and methods of induction of a cellular stress response and a protected phenotype using heavy metal ions. The invention relates to methods of protecting a mammal against injury caused by a noxious condition by administering to the mammal a heavy metal in sufficient quantity and under appropriate conditions to induce a sufficient cellular stress response to provide protection (partial or complete) against injury caused by a noxious condition. The invention also relates to methods of inducing a cellular stress response in a mammal by administering a heavy metal in sufficient quantity and under appropriate conditions to induce a cellular stress response to protect the mammal against injury caused by a noxious condition.
    Type: Application
    Filed: January 11, 2001
    Publication date: September 13, 2001
    Inventor: George A. Perdrizet
  • Patent number: 6242009
    Abstract: Microbicidal formulations are described which are preferably ecologically friendly and non-toxic to mammals, and are highly effective against a broad spectrum of detrimental pathogenic microorganisms. The microbicidal formulation contains complexes having the formula R-M, wherein R is at least one organic chelating moiety and M is at least one metal ion which is microbicidal to at least one microorganism. These complexes can disrupt microorganism activities by penetrating the natural protecting bio-films of such microorganisms through the reaction of the R-group with the organic constituents of these microorganisms while releasing M into their intra-cellular media. Thus, this process exhibits its biocidal activities from the inside-out, contrary to other methods which rely on damaging the protective biofilms.
    Type: Grant
    Filed: April 20, 1999
    Date of Patent: June 5, 2001
    Inventors: Kareem I. Batarseh, Marwan Al-Kayed
  • Patent number: 6187290
    Abstract: There is described a foamable formulation comprising a foamable carrier and an active ingredient which may be admixed with the carrier or packaged separately and dispersed into the carrier during the foaming process. Alginate gel is a preferred foamable carrier. The foam produced from such a formulation, and a foam sheet produced by drying the foam, also form part of the invention. The formulation, foam and foam sheet are especially useful for medical applications, for example in treating burns. As apparatus to store the components of the formulation and to generate the foam is also described.
    Type: Grant
    Filed: May 7, 1997
    Date of Patent: February 13, 2001
    Assignee: Giltech Limited
    Inventors: Thomas Gilchrist, Eilidh Gilchrist
  • Patent number: 5846572
    Abstract: A sterile, pyrogen-free fluid replacement solution for intravenous infusion is disclosed that consists essentially of a physiologically acceptable sodium salt, a physiologically acceptable potassium salt, an osmolality control agent, and, optionally, a component selected from the group consisting of a physiologically acceptable calcium salt and a physiologically acceptable magnesium salt.
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: December 8, 1998
    Assignee: East & Midlothian NHS Trust
    Inventor: Francis George Richard Prior
  • Patent number: 5709890
    Abstract: An insecticide composition is enhanced from the standpoint of its ability to be absorbed by insects, such as red fire ants, particularly dithiophosphate ester pesticides by the addition of a small amount of a water soluble non-aromatic polyorganic acid or salt form thereof such as polyaspartic acid, particularly preferred with a molecular weight in the range of about 3000 to 40,000.
    Type: Grant
    Filed: March 20, 1997
    Date of Patent: January 20, 1998
    Assignee: Donlar Corporation
    Inventor: J. Larry Sanders
  • Patent number: 5618762
    Abstract: An antibacterial ceramic contains an antibacterial material produced by loading an antibacterial metal such as silver on a calcium ceramic carrier and an inorganic material such as cordierite, and has a bulk density of 0.6-1.2 g/cm.sup.3. An antibacterial ceramic filter contains an antibacterial material produced by loading an antibacterial metal such as silver on a calcium ceramic carrier, an aggregate such as mullite, and a binder such as frit, and has a porosity of 20% or more. The light-weight antibacterial ceramic is suitably applicable to a roof garden or the like. The antibacterial ceramic filter can remove and extirpate various bacteria and suspensions.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: April 8, 1997
    Assignees: NGK Insulators, Ltd., NGK Adrec Co. Ltd., Sangi Co. Ltd.
    Inventors: Hiroshi Shirakawa, Osamu Yamakawa, Hiroaki Nihonmatsu, Kiminori Atsumi
  • Patent number: 5597550
    Abstract: An apparatus and process for administering minerals to the human body by mixing pre-selected particulated minerals with graphite and coal tar to form a bar (10a), vaporizing the bar (10a) to form a mineral rich vapor, and directing the vapor to a patient's skin using an enclosure (30).
    Type: Grant
    Filed: December 9, 1994
    Date of Patent: January 28, 1997
    Inventor: Buxing Mo